Tenderwize
Wróć do wyszukiwania

Open House Discount Agreements for Cabotegravir (Depot Injection Suspension)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 584 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cabotegravir in der Darreichungsform Depot-Injektionssuspension, ATC J05AJ04

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated value or guaranteed purchase volume; participation may not yield significant business.

Open-house model is not subject to procurement law; legal recourse lies with social courts, not procurement chambers.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Conclusion of non-exclusive discount agreements for Cabotegravir (ATC J05AJ04) in depot injection suspension form.
  • Agreements are identical for all participants and not individually negotiable.
Pokaż pełne podsumowanie

AOK Bayern is offering non-exclusive discount agreements under an open-house model for the pharmaceutical product Cabotegravir (ATC J05AJ04, depot injection suspension) to all interested pharmaceutical companies that meet eligibility criteria. The contract runs from June 2026 to May 2028, with possible termination under certain conditions. This is not a standard procurement procedure; participation is open, but no estimated value is provided.

Ryzyka

No estimated value or guaranteed purchase volume; participation may not yield significant business.

Open-house model is not subject to procurement law; legal recourse lies with social courts, not procurement chambers.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible.

Administrative

  • Submission of a signed self-declaration of reliability, signed contract, and filled annex on medicinal products.
  • Documents must be submitted either in paper form (two original copies) or electronically with a qualified electronic signature.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open House Discount Agreements for Cabotegravir (Depot Injection Suspension)

Single lot covering all agreements for Cabotegravir. The open-house model allows any eligible pharmaceutical company to conclude identical, non-negotiable discount agreements. The contract period is from 01.06.2026 to 31.05.2028, with rolling monthly cutoff for document submission.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

May 2026 - May 2028

Kategoria

Pharmaceutical products

Termin

Deadline Apr 03, 2028

Szczegóły zamówienia

Data publikacji
14 Apr 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
257297-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30